Global bioscience company Chr. Hansen is already a strong player in probiotics for infant formula and entered the promising market for Human Milk Oligosaccharides in 2020.
We caught up with one of their senior scientists, Stina Jensen at our Probiota conference in Copenhagen where she explained a little more about what the company is trying to achieve.
The development of a balanced microbiota – the bacterial colonisation of our bodies – is key to health later in life, and it develops during the first years of our lives. Therefore, it is valuable to ensure that formula-fed babies, to the greatest extent possible, can have a good start in life by developing a bacterial profile closer to breastfed children, dominated by Bifidobacteria.
HMOs are important groups of milk sugars found only in human breast milk, providing different health benefits to infants in helping to develop a healthy digestive system and supporting the immune system and brain development.
